Compare GOGO & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOGO | KROS |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 566.2M | 584.9M |
| IPO Year | 2011 | 2020 |
| Metric | GOGO | KROS |
|---|---|---|
| Price | $4.18 | $11.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $15.00 | ★ $21.86 |
| AVG Volume (30 Days) | ★ 1.3M | 308.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | 0.09 | ★ 2.30 |
| Revenue | ★ $910,491,000.00 | $243,864,000.00 |
| Revenue This Year | $3.68 | N/A |
| Revenue Next Year | $3.60 | $2,751.79 |
| P/E Ratio | $44.17 | ★ $4.81 |
| Revenue Growth | ★ 104.74 | N/A |
| 52 Week Low | $3.85 | $10.42 |
| 52 Week High | $16.82 | $22.55 |
| Indicator | GOGO | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 40.85 |
| Support Level | $4.17 | $10.56 |
| Resistance Level | $5.07 | $12.65 |
| Average True Range (ATR) | 0.23 | 0.35 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 24.19 | 22.48 |
Gogo Inc is a broadband connectivity service for the business aviation market. It provides a customizable suite of smart cabin systems for integrated connectivity, inflight entertainment, and voice solutions. Its business segment includes Gogo BA and Satcom Direct. It generates two types of revenue: service revenue consists of monthly subscription and usage fees paid by aircraft owners and operators for telecommunication, data, and in-flight entertainment services, and equipment revenue consists of proceeds from the sale of ATG and narrowband satellite connectivity equipment and is recognized when control of the equipment is transferred to OEMs and dealers, which generally occurs when the equipment is shipped.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.